Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma

Authors: Zangari, Maurizio; Cavallo, Federica; Tricot, Guido

Source: Current Pharmaceutical Biotechnology, Volume 7, Number 6, December 2006 , pp. 449-453(5)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Multiple myeloma (MM) is a B-cell malignancy characterized by an accumulation of long-lived neoplastic plasma cells (PC) within the bone marrow (BM). Novel treatments are not only targeting myeloma cells but also directly interfere with myeloma-stromal cell interactions, interrupting signal transduction pathways. Farnesyltransferase inhibitors (FTIs) and rapamycin represent novel classes of signal transduction inhibitors targeting principally Ras/MAPK and PI3K/Akt pathway. Pre-clinical and early clinical reports are presented in this study.

Keywords: CAAX binding site; Tipifarnib; STAT3 tyrosine phosphorylation; mTOR Kinase pathway; CCI-779; haematological malignancies

Document Type: Research article

DOI: http://dx.doi.org/10.2174/138920106779116838

Affiliations: 1: Myeloma Institute for Research and Therapy University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Publication date: 2006-12-01

More about this publication?

Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics in both pre-clinical and clinical areas of Pharmaceutical Biotechnology. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.